(Q42875432)

9 November 2017

title

Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model (English)

1 reference

9 November 2017

0 references

1 reference

11

1 reference

9 November 2017

W A Wuyts

1

1 reference

9 November 2017

S Willems

2

1 reference

9 November 2017

R Vos

3

1 reference

9 November 2017

B M Vanaudenaerde

4

1 reference

9 November 2017

S I De Vleeschauwer

5

1 reference

9 November 2017

M Rinaldi

6

1 reference

9 November 2017

H M Vanhooren

7

1 reference

9 November 2017

N Geudens

8

1 reference

9 November 2017

S E Verleden

9

1 reference

9 November 2017

M G Demedts

10

1 reference

9 November 2017

E K Verbeken

12

1 reference

9 November 2017

G M Verleden

13

1 reference

9 November 2017

publication date

27 September 2010

1 reference

Experimental Lung Research

9 November 2017

published in

1 reference

9 November 2017

volume

36

1 reference

9 November 2017

issue

10

1 reference

9 November 2017

page(s)

602-614

1 reference

Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?

9 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

High-dose acetylcysteine in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Macrolide therapy targets a specific phenotype in respiratory medicine: from clinical experience to basic science and back

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Neutrophilic alveolitis in idiopathic pulmonary fibrosis. The role of interleukin-8

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Circulating and intrapulmonary C-reactive protein: a predictor of bronchiolitis obliterans syndrome and pulmonary allograft outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

The IL-23/IL-17 axis in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Neutrophils, interleukin-17A and lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Azithromycin reduces airway inflammation in a murine model of lung ischaemia reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Effect of azithromycin on primary bronchial epithelial cells derived from stable lung allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Anti-inflammatory effects of macrolides in lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Cellular and molecular mechanisms of fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Time course of bleomycin-induced lung fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Pulmonary fibrosis: searching for model answers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

Biphasic effects of free radical scavengers against bleomycin-induced pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

A Phase I Determination of Azithromycin in Plasma during a 6-Week Period in Normal Volunteers after a Standard Dose of 500mg Once Daily for 3 Days

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.492895

10.3109/01902148.2010.492895

21 January 2018

Identifiers

DOI

1 reference

9 November 2017

1 reference